(24/7 MARKET NEWS) – BullFrog AI Holdings, Inc. (NASDAQ: BFRG) reported, this morning, positive preclinical data from a study investigating the anti-cancer activity assessing the relative efficacy of BF-222, a novel formulation of mebendazole that has been evaluated in clinical trials, and BF-223, a novel prodrug of mebendazole with improved solubility and bioavailability relative to BF-222, compared with placebo in mice that had been implanted with tumor cells, for the treatment of glioblastoma.
BullFrog AI is trading at $3.22, up $0.35 (+12.20%), on 1.58M premarket shares traded.
Its 52-week range is $2.47 to $9.50. its next key inflection point is $3.43.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.